On-Demand webinar
Summary:
In the U.S. there are 8 million ER visits per year reporting chest pain, a common symptom of AMI.1,2 Yet only less than 10 percent of those patients are actually having an AMI.2 Using a true High-Sensitivity Troponin I assay, can aid in effectively triaging patients suspected of an AMI.
The diagnosis of acute myocardial infarction (MI) poses a challenge for clinicians, particularly in the absence of clear ECG evidence. In 2018, a consensus conference of experts reinforced and extended the definition of MI based on cardiac biomarkers and proposed high sensitivity troponin as the preferred cardiac biomarker. These recommendations were published in an article entitled The Fourth Universal Definition of Myocardial Infarction. This document reinforced previous recommendations that advocated for the use of the troponin medical decision to be the 99th percentile of a normal population with a <10% CV at that level as well as defining the features of high sensitivity troponin.
Speaking on these findings, Dr. Jim Aguanno, Ph.D. senior clinical consultant at Siemens Healthineers, will help you:
- Describe the difference between contemporary and high sensitivity troponin assays
- Describe the use of high sensitivity troponin for the early diagnosis of MI
- Discuss using various options for the implementation of high sensitivity troponin
Speaker:
Dr. Jim Aguanno, Ph.D.
Senior Clinical Consultant, Siemens Healthineers.
Dr. Jim Aguanno has over 40 years of experience in laboratory medicine. He received a Bachelor of Science in Chemistry and a Ph.D. in Biochemistry from Memphis State University. Following his Ph.D., he did two post-doctoral fellowships one at the University of Pittsburgh School of Medicine in Biochemistry and a second fellowship in Laboratory Medicine at Washington University School of Medicine and Barnes Hospital in St. Louis, Missouri. Dr. Aguanno was Director of the Core Laboratory at Baylor University Medical Center in Dallas, Texas for 24 years. Dr. Aguanno joined Siemens Healthcare Diagnostics in January of 2004 and is currently Senior Clinical Consultant in the Clinical and Scientific Affairs group focusing on cardiovascular disease, infectious diseases and general aspects of laboratory medicine.
